Think of Inclisiran as a Niche Med for Lowering LDL

February 2022

Inclisiran (Leqvio) will be the first "small interfering RNA" therapy for lowering cholesterol.

This injectable works at a different step in the same pathway as the PCSK9 inhibitors, alirocumab (Praluent) and evolocumab (Repatha).

Inclisiran prevents formation of the PCSK9 protein...alirocumab and evolocumab prevent PCSK9 binding.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote